Hashimoto's thyroiditis
Conditions
Interventions
Control Group:Placebo
Research Group:Qinggan Sanjie Xiaoying granule
Sponsors
Sun Simiao Hospital of Beijing University of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1)34 IU/ml < TPOAb < 600 IU/ml (2)TGAb < 4000 IU/ml (3)TRAB(-); (4) Thyroid ultrasound showed diffuse enlargement or heterogeneous echo; (5) 18 to 70 years old; (6) Thyroid hormones (FT3, FT4, T3, T4) were within the reference range; (7) Elevated levels of thyroid stimulating hormone (subclinical hypothyroidism); (8) Drug washout period: no clinical trial, immune preparation and Chinese medicine were conducted within 3 months before enrollment; (9) No drugs affecting thyroid hormone metabolism, including corticosteroids, preparations containing vitamins or trace elements, amiodarone a Interferons, lithium preparations, antidepressants or antipsychotics, etc; (10) Did not participate in other clinical studies; (11) I signed the informed consent to participate in this study.
Exclusion criteria
Exclusion criteria: (1) Previous or current thyroid diseases, including nodular goiter, hyperthyroidism or subclinical hyperthyroidism, or history of thyroid surgery, radiation iodine therapy, Graves disease; (2) Abnormal liver function (ALT and AST exceed the upper limit of normal value), abnormal renal function (Cr and BUN exceed the upper limit of normal value); (3) Women who are pregnant, lactating or preparing for pregnancy; (4) Serious systemic diseases, such as heart failure (NYHA grade III / IV), severe arrhythmia, unstable angina pectoris, and myocardial infarction within half a year; Acute stroke or severe sequelae, without cognitive ability or unable to take care of themselves and cooperate; (5) Suffering from other immune system diseases; (6) Suffering from malignant tumor; (7) Allergic to the test drug; (8) Surgery or other stress conditions, as well as mental illness, drug or other substance abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TPOAb; | — |
Secondary
| Measure | Time frame |
|---|---|
| TGAb;TSH;ultrasound;T4;ThyPRO39;T3;FT4;FT3; | — |
Countries
China
Contacts
Public ContactZhiguo Ding
Outcome results
None listed